

## Special Issue

# Epidemiology, Complications and Management of Diabetes

### Message from the Guest Editor

Type II diabetes mellitus (T2DM) is a severe metabolic disorder, characterized by chronic hyperglycemia associated with increased glucose cell toxicity, that leads to irreversible renal and pancreatic cell damage. Autophagy/klotho pathways play a key role in damaged intracellular protein degradation, intracellular homeostasis, and cell integrity maintenance. Recent studies have shown a decrease in  $\beta$ -klotho and autophagy proteins (ATG5/LC3-II) as well as in the expression of DMs' kidney and pancreatic  $\beta$  cells. Both  $\beta$ -klotho and autophagy key proteins can play a protective role against DM complications, such as diabetic nephropathy. Empagliflozin, a sodium-glucose transporter-2 inhibitor, is currently used for patients with T2DM to lower plasma glucose levels and normalize HbA1C, yet it bears pleiotropic effects on kidney and pancreatic  $\beta$  cells. Chronic glucose exposure damages renal epithelial and  $\beta$  cells via the downregulation of klotho and autophagy processes.

### Guest Editor

Prof. Dr. Farid M. Nakhoul

1. The Cardiovascular and Diabetes Lab, Research Institute, The Galilee Medical Center, Nahariya, Israel
2. The Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel

### Deadline for manuscript submissions

closed (20 April 2023)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/131599](https://mdpi.com/si/131599)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).